TIDMNCYT
RNS Number : 5270I
Novacyt S.A.
22 March 2018
NOVACYT SIGNS ASSAY DEVELOPMENT CONTRACT FOR DIAGNOSIS OF
RESPIRATORY INFECTIONS WITH GENEPOC
Further validation of Novacyt's expertise in
developing assays for clinical applications
Paris, France and Camberley, UK - 22 March 2018 - Novacyt
(EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in
clinical diagnostics, today announces its molecular testing
division, Primerdesign, has entered into a clinical assay
development contract with GenePOC Inc., a Canada-based company and
member of the Debiopharm Group(TM), which specialises in the
development and manufacture of molecular diagnostic devices for the
detection of infectious diseases closer to the patient.
Under the terms of the services agreement, Primerdesign will
develop a triplex molecular diagnostic assay to identify influenza
A, influenza B and respiratory syncytial virus A and B (RSV A and
B) which will subsequently be run on GenePOC's revogene(TM)
instrument. GenePOC will seek regulatory clearance for the assay in
the US through the US Food and Drug Administration (FDA) and CE-IVD
marking in Europe under the In Vitro Diagnostic Directive.
The World Health Organisation ("WHO") states influenza spreads
around the world in a yearly outbreak. In annual influenza
epidemics, 5-10% of the world's population are affected with upper
respiratory tract infections, resulting in approximately three to
five million cases of severe illness and approximately 250,000 to
500,000 deaths(1) .
Graham Mullis, Group CEO of Novacyt, commented:
"I am delighted that we are entering into this clinical
development agreement with GenePOC, a leader in the provision of
high-speed, high-quality and on-the-spot molecular diagnostic
devices to healthcare practitioners. This marks our first
significant business-to-business clinical development contract win
in 2018 and adds further momentum to our business-to-business
segment following material contract wins in China for both
Primerdesign and NOVAprep(R) ."
"GenePOC is an ideal partner given their expertise in developing
accurate and cost effective molecular solutions to detect
infectious diseases. GenePOC has already received US Food and Drug
Administration clearance and CE marking for an assay to diagnose
hospital acquired infections, as well as CE marking for a neonatal
diagnostic assay. We look forward to working with GenePOC and
building on this important partnership."
Patrice Allibert, PhD, CEO of GenePOC, commented:
"I am pleased to enter into a partnership with Novacyt, an
expert in molecular diagnostic assay development. We were impressed
with Primerdesign's ability to rapidly develop assays and track
record of CE marking diagnostic tests. I am confident that they are
the right partner to help us deliver the technically challenging
multiplexed respiratory disease assay and, in combination with our
near patient testing revogene(TM) platform, this will improve
clinical outcomes for patients around the world."
- End -
References
(1) WHO publication: A manual for estimating disease burden
associated with seasonal influenza. Published in 2015. ISBN 978 924
154930 1
Contacts
Novacyt SA
Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1223 395472
Stifel Nicolaus Europe Limited (Nominated Advisor and Joint
Broker)
Jonathan Senior / Fred Walsh / Ben Maddison
+44 (0)20 7610 7600
WG Partners (Joint Broker)
Nigel Birks / Chris Lee / Claes Spång
+44 (0)203 705 9330
FTI Consulting (International)
Brett Pollard / Victoria Foster Mitchell
+44 (0)20 3727 1000
brett.pollard@fticonsulting.com /
victoria.fostermitchell@fticonsulting.com
FTI Consulting (France)
Arnaud de Cheffontaines / Astrid Villette
+33 (0)147 03 69 47 / +33 (0)147 03 69 51
arnaud.decheffontaines@fticonsulting.com /
astrid.villette@fticonsulting.com
About Novacyt Group
The Novacyt Group is a rapidly growing, international
diagnostics group with a growing portfolio of cancer and infectious
disease products and services. Through its proprietary technology
platform, NOVAprep(R), and molecular platform, genesig(R), Novacyt
is able to provide an extensive range of oncology and infectious
disease diagnostic products across an extensive international
distributor network. The Group has diversified sales from
diagnostic reagents used in oncology, microbiology, haematology and
serology markets, and its global customers and partners include
major corporates.
For more information please refer to the website:
www.novacyt.com
About GenePOC
GenePOC, a member of the Debiopharm Group(TM), specializes in
diagnostic devices for the prevention and detection of infectious
diseases. The company aims to become the market leader in rapid
microbial testing. GenePOC's revogene(TM) instrument is also
available in the US and EU markets with a rapidly expanding test
menu.
GenePOC's revogene(TM) platform is a fully automated instrument
for processing clinical samples, performing homogenization,
microorganism lysis, dilution, amplification and detection of
target nucleic acid sequences from multiple specimens using
fluorescence-based real-time PCR. Its unique design, combining a
compact platform and a single-use microfluidic cartridge (PIE),
enables automated nucleic acid-based testing of infectious
microorganisms. During a 70 minute total run time, the revogene(TM)
has the ability to process eight clinical samples simultaneously,
detecting up to 12 genetic targets per sample. With its integrated
and user friendly touch screen, the revogene(TM) allows medical
staff to easily and efficiently perform molecular diagnostic
tests.
Further information: www.genepoc-diagnostics.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTFKDDPKBKBKNB
(END) Dow Jones Newswires
March 22, 2018 03:01 ET (07:01 GMT)
Novacyt (LSE:NCYT)
Historical Stock Chart
From Apr 2024 to May 2024
Novacyt (LSE:NCYT)
Historical Stock Chart
From May 2023 to May 2024